High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill

Gynecological Endocrinology

Volumn 19, Issue 4, 2004, Pages 190-195

  Guzelmeric, K ^a   Seker, N ^a   Unal, O ^a   Turan, C ^a  

^a Dr Lutfi Kirdar Kartal Educ Res H ^*  (Turkey)

Author keywords

Hirsutism; Oral contracptive; Prostate specific antigen; Spironolactone

Indexed keywords

ANDROGEN; BIOCHEMICAL MARKER; ETHINYLESTRADIOL; GESTODENE; HYDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; SPIRONOLACTONE; TESTOSTERONE;

ADULT; ARTICLE; BIOCHEMISTRY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIRSUTISM; HORMONE ACTION; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CONTRACEPTIVES, ORAL; DEHYDROEPIANDROSTERONE SULFATE; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; NORPREGNENES; PROSTATE-SPECIFIC ANTIGEN; SPIRONOLACTONE; TESTOSTERONE;

EID: 12244259735     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400012069     Document Type: Article

References (15)

1. McCormack RT, Rittenhouse HG, Finlay JA. Molecular forms of prostate specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44
2. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of human prostate-specific antigen. Invest Urol 1979;17:159-63
3. Catalona WJ, Smith DS, Ratliff TL. Measurment of prostate specific antigen in serum as a screening test for prostate cancer. Engl J Med 1991;324:1156-61
4. Diamandis EP. Prostate specific antigen - new applications in breast and other cancers. Anticancer Res 1996;16:3983-4
5. Diamandis EP. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24:275-82
6. Melegos DN, Yu H, Ashok M, et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997;82:777-80
7. Escobar-Morreale HF, Serrano-Gotarredona J, Varela C, et al. The increased circulating prostate-specific antigen concentrations in woman with hirsutism do not respond to acute changes in adrenal and ovarian function. J Clin Endocrinol Metab 1998;83:2580-4
8. Escobar-Morreale HF, Avila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Matab 2000;85:2488-92
9. Negri C, Tosi F, Dorizzi R. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 2000;85:81-4
10. Young RL, Goldzieher JW, Elkind-Hirsch K. The endocrine effects of spironolactone used as an antiandrogen. Fertil Steril 1987;48:223
11. Pittaway DE, Maxson WS, Wentz AC. Spironolactone in combination drug therapy for unresponsive hirsutism. Fertil Steril 1985;43:878
12. Mauvais-Jarvis P. Regulation of androgen receptor and 5-alpha-reductase in the skin of normal and hirsute women. J Clin Endocrinol Metab 1996;15:307-17
13. Darney PD. The androgenicity of progestins. Am J Med 1995;98:1040-110
14. Yu H, Diamandis EP, Monne M, et al. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 1995;270:6615-8
15. Witherspoon LR, Lpeyrolerie T. Sensitive prostate-specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997;157:1322-8